Corbus Pharmaceuticals
CRBP
20 hedge funds and large institutions have $7.81M invested in Corbus Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
43% more funds holding
Funds holding: 14 → 20 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less capital invested
Capital invested by funds: $9.54M → $7.81M (-$1.73M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$2.22M |
| 2 |
PA
Perceptive Advisors
New York
|
+$843K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$401K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$202K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$202K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$3K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.73K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$1.47K |
CRBP Hedge Fund Activity: Q3 2015 in Review
20 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q3 2015, worth a combined $7.81M — down 18% from $9.54M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CRBP positions and 1 closed out — a net gain of 6 holders — while 9 added to existing stakes and 3 trimmed.
The largest buyer was Knoll Capital Management, adding an estimated $2.22M. The largest seller was BlackRock Fund Advisors, cutting an estimated $3K.
- 20 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q3 2015, up from 14 in Q2 2015.
- Funds reported $7.81M of Corbus Pharmaceuticals stock for Q3 2015, down 18% quarter-over-quarter.
- 7 funds opened new Corbus Pharmaceuticals positions in Q3 2015 and 1 closed out, a net change of +6 holders.
- The largest Corbus Pharmaceuticals buyer in Q3 2015 was Knoll Capital Management, an estimated $2.22M added.
- The largest Corbus Pharmaceuticals seller in Q3 2015 was BlackRock Fund Advisors, an estimated $3K sold.
Based on aggregated 13F filings for Q3 2015.